Clinical Trial Update: A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing risankizumab to placebo in adults with active psoriatic arthritis who had inadequate response or intolerance to at least one DMARD; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• SKYRIZI (risankizumab-rzaa)

Snippet

Sponsor: AbbVie | Conditions: Psoriatic Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-02-24